Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

NCT ID: NCT01820169

Last Updated: 2016-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical study is to determine if the use of structured testing, which is a blood glucose monitoring, via the Accu-Chek 360° View blood glucose analysis tool has a positive effect on the subjects overall glycemic control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm

Group Type EXPERIMENTAL

;Accu-Chek Compact Plus LCM bulk Japan

Intervention Type DEVICE

HbA1c would be changed by more careful control in blood glucose with SMBG.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

;Accu-Chek Compact Plus LCM bulk Japan

HbA1c would be changed by more careful control in blood glucose with SMBG.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Age:= and \>20 years. 2. Intend to paticipate in this study after education of structured testing. 3.HbA1c:= and \>7.5% in the recect 2 months.

Exclusion Criteria

1.Pregancy. 2. Heavy complication 3. judged unsuitable by doctor
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Naoki Sakane

Role: PRINCIPAL_INVESTIGATOR

National organization Hospital Kyoto Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kyoto, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD001551

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glucose Monitoring Comparison in Primary Care
NCT05222815 ACTIVE_NOT_RECRUITING NA